The purpose of the RCT trial is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of composite event of any stroke and death within 30 days after enrollment and ischemic stroke in the territories of the responsible artery from 31 days to 1-year after enrollment than optimal medical treatment for symptomatic intracranial atherosclerotic stenosis.
This trial is a prospective, multi-center, 1:1 randomized using drug-eluting (Sirolimus) stent combined with aggressive medical treatment versus optimal medical treatment to treat intracranial stenosis of 70-99% degree. The primary endpoint is any stroke and death within 30 days after enrollment or after revascularization procedure of the qualifying lesion during follow-up, ischemic stroke in the territories of the responsible artery from 31 days to 1-year after enrollment.
| Condition | cerebrovascular accidents, Cerebrovascular accident, Cerebral Atherosclerosis, strokes, cerebral, intracranial atherosclerosis, Stroke |
|---|---|
| Treatment | Standard Medical Treatment, Drug Eluting Stent implantation, Aggressive medical treatment, Risk factor management |
| Clinical Study Identifier | NCT04948749 |
| Sponsor | Beijing Tiantan Hospital |
| Last Modified on | 23 September 2023 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.